Anti-CD22 (Epratuzumab)-MCC-DM1 ADC

  • Check with publisher
  • Published date: November 13, 2017
    • Shirley, New York, United States

This ADC product is comprised of a Epratuzumab conjugated via a MCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation. Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.

Result 0 votes
Bella
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-CD22 (Epratuzumab)-Mc-MMAF ADC

    Anti-CD22 (Epratuzumab)-Mc-MMAF ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Epratuzumab conjugated via a MC linker to a MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubuli...

  • Anti-CD22 (Epratuzumab)-CL2E-SN-38 ADC

    Anti-CD22 (Epratuzumab)-CL2E-SN-38 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an a Epratuzumab conjugated via a CL2E linker to a SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. The SN-38 is targeted to certa...

  • Anti-CD22 (Epratuzumab)-CL2A-SN-38 ADC

    Anti-CD22 (Epratuzumab)-CL2A-SN-38 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an a Epratuzumab conjugated via a CL2A linker to a SN-38.The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis.The SN-38 is targeted to certain...